Abstract
Cancer is a leading cause of death and a severe threat to global public health. Organoid,
as a novel 3D in vitro model, has been applied in various tumor related studies due to its apparent
advantages. The organoid is mainly constructed by Matrigel-depended 3D culture system,
Air-Liquid Interface (ALI) culture, and Microfluidic culture or Organ-on-chips platform. For the
application in carcinogenesis studies, the organoid model may favor depicting initiative hallmarks
and identifying potential intervening targets, investigating driver genes of carcinogenesis,
and identifying known or unknown risk or protective factors.
In this review, we discussed different organoid construction methods and their properties. We also
noted that tumor organoids can portray initiative hallmarks and identify possible intervening
targets, as well as explore carcinogenesis driver genes and uncover known or unknown risks or
protective factors. Organoid systems have been used to identify tumor-preventive drugs such as
oligomeric proanthocyanidins, Vitamin D, n-3 PUFAs, and pomegranate. The current evidence
underscores the organoid model's potential importance in developing innovative tumorprevention
techniques.
Keywords:
Organoid, 3D model, tumorigenesis, pharmacology, oncogenic prevention, cancer.
Graphical Abstract
[9]
Li, S.; Shen, D.; Shao, J.; Crowder, R.; Liu, W.; Prat, A.; He, X.; Liu, S.; Hoog, J.; Lu, C.; Ding, L.; Griffith, O.L.; Miller, C.; Larson, D.; Fulton, R.S.; Harrison, M.; Mooney, T.; McMichael, J.F.; Luo, J.; Tao, Y.; Goncalves, R.; Schlosberg, C.; Hiken, J.F.; Saied, L.; Sanchez, C.; Giuntoli, T.; Bumb, C.; Cooper, C.; Kitchens, R.T.; Lin, A.; Phommaly, C.; Davies, S.R.; Zhang, J.; Kavuri, M.S.; McEachern, D.; Dong, Y.Y.; Ma, C.; Pluard, T.; Naughton, M.; Bose, R.; Suresh, R.; McDowell, R.; Michel, L.; Aft, R.; Gillanders, W.; DeSchryver, K.; Wilson, R.K.; Wang, S.; Mills, G.B.; Gonzalez-Angulo, A.; Edwards, J.R.; Maher, C.; Perou, C.M.; Mardis, E.R.; Ellis, M.J. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Cell Rep., 2013,
4(6), 1116-1130.
[
http://dx.doi.org/10.1016/j.celrep.2013.08.022] [PMID:
24055055]
[26]
Boj, S.F.; Hwang, C.I.; Baker, L.A.; Chio, I.I.; Engle, D.D.; Corbo, V.; Jager, M.; Ponz-Sarvise, M.; Tiriac, H.; Spector, M.S.; Gracanin, A.; Oni, T.; Yu, K.H.; van Boxtel, R.; Huch, M.; Rivera, K.D.; Wilson, J.P.; Feigin, M.E.; Öhlund, D.; Handly-Santana, A.; Ardito-Abraham, C.M.; Ludwig, M.; Elyada, E.; Alagesan, B.; Biffi, G.; Yordanov, G.N.; Delcuze, B.; Creighton, B.; Wright, K.; Park, Y.; Morsink, F.H.; Molenaar, I.Q.; Borel Rinkes, I.H.; Cuppen, E.; Hao, Y.; Jin, Y.; Nijman, I.J.; Iacobuzio-Donahue, C.; Leach, S.D.; Pappin, D.J.; Hammell, M.; Klimstra, D.S.; Basturk, O.; Hruban, R.H.; Offerhaus, G.J.; Vries, R.G.; Clevers, H.; Tuveson, D.A. Organoid models of human and mouse ductal pancreatic cancer.
Cell, 2015,
160(1-2), 324-338.
[
http://dx.doi.org/10.1016/j.cell.2014.12.021] [PMID:
25557080]
[31]
Sachs, N.; Papaspyropoulos, A.; Zomer-van Ommen, D.D.; Heo, I.; Böttinger, L.; Klay, D.; Weeber, F.; Huelsz-Prince, G.; Iakobachvili, N.; Amatngalim, G.D.; de Ligt, J.; van Hoeck, A.; Proost, N.; Viveen, M.C.; Lyubimova, A.; Teeven, L.; Derakhshan, S.; Korving, J.; Begthel, H.; Dekkers, J.F.; Kumawat, K.; Ramos, E.; van Oosterhout, M.F.; Offerhaus, G.J.; Wiener, D.J.; Olimpio, E.P.; Dijkstra, K.K.; Smit, E.F.; van der Linden, M.; Jaksani, S.; van de Ven, M.; Jonkers, J.; Rios, A.C.; Voest, E.E.; van Moorsel, C.H.; van der Ent, C.K.; Cuppen, E.; van Oudenaarden, A.; Coenjaerts, F.E.; Meyaard, L.; Bont, L.J.; Peters, P.J.; Tans, S.J.; van Zon, J.S.; Boj, S.F.; Vries, R.G.; Beekman, J.M.; Clevers, H. Long-term expanding human airway organoids for disease modeling.
EMBO J., 2019,
38(4), e100300.
[
http://dx.doi.org/10.15252/embj.2018100300] [PMID:
30643021]
[50]
Vlachogiannis, G.; Hedayat, S.; Vatsiou, A.; Jamin, Y.; Fernández-Mateos, J.; Khan, K.; Lampis, A.; Eason, K.; Huntingford, I.; Burke, R.; Rata, M.; Koh, D.M.; Tunariu, N.; Collins, D.; Hulkki-Wilson, S.; Ragulan, C.; Spiteri, I.; Moorcraft, S.Y.; Chau, I.; Rao, S.; Watkins, D.; Fotiadis, N.; Bali, M.; Darvish-Damavandi, M.; Lote, H.; Eltahir, Z.; Smyth, E.C.; Begum, R.; Clarke, P.A.; Hahne, J.C.; Dowsett, M.; de Bono, J.; Workman, P.; Sadanandam, A.; Fassan, M.; Sansom, O.J.; Eccles, S.; Starling, N.; Braconi, C.; Sottoriva, A.; Robinson, S.P.; Cunningham, D.; Valeri, N. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
Science, 2018,
359(6378), 920-926.
[
http://dx.doi.org/10.1126/science.aao2774] [PMID:
29472484]